AbbVie slammed over ‘drip feed’ of Imbruvica patents

20-07-2020

Rory O'Neill

AbbVie slammed over ‘drip feed’ of Imbruvica patents

OleksandrShnuryk / Shutterstock.com

AbbVie has used a “drip feed” of patents to secure more than nine years of extra exclusivity on blood cancer drug Imbruvica (ibrutinib), a new report has revealed.


AbbVie, Imbruvica, patents, I-MAK, report, lymphoma, leukemia, ibrutinib, FDA

LSIPR